Resmed Inc

Company facts

Industry

Surgical & Medical Instruments & Apparatus

Headquarters

San Diego, California

Most recent report

10-Q, filed Oct 30, 2026

Incorporated

Delaware

Filings on record

1,004+ filings

On EDGAR

CIK 943819

Fiscal year ends

June

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 13 sections worth reading, with 0 positive, 14 notable, and 1 negative flags.

• Financial Statements (Item 1)

  Financial statements and notes with debt paydown, buyback, divestiture gain, and customer concentration.
  Notable

  • Bought back 3.6M shares for $855M in Q1 FY2027, including a $450M ASR; 4.3M shares remain authorized.
  • Restructuring charges of $19M in Q1 FY2027, up from $16M a year ago, for growth and workforce initiatives.
  Negative

  • One customer grew to 11% of total revenue in Q1 FY2027, up from none at 10%+ in the prior year.

• Management's Discussion (Item 2)

  MD&A with segment results, divestiture gain, buyback, and cash flow details.
  Notable

  • Revenue up 6% to $1.4B in Q1 FY2027; Sleep and Breathing Health up 8%, Residential Care Software down 7%.
  • Gross margin improved to 61.5% from 61.2% in Q1 FY2027, helped by manufacturing efficiencies and lower amortization.
  • R&D spending rose 15% to $103M in Q1 FY2027, now 7.3% of revenue vs 6.7% a year ago.
  • SG&A rose 12% to $315M in Q1 FY2027, including $20M restructuring and $10M acquisition/divestment costs.
  • Net income up 20% to $418M in Q1 FY2027, but includes a $62M one-time gain from MatrixCare sale.
  • Cash and equivalents fell to $1.0B at Sep 30, 2026 from $1.5B at Jun 30, 2026, after buyback and debt repayment.
  • Entered $450M accelerated share repurchase on Aug 31, 2026; funded partly by MatrixCare sale proceeds.
  • Repaid $250M of 3.24% senior notes in July 2026; $410M total debt outstanding at Sep 30, 2026.
  • Operating cash flow fell 8% to $422M in Q1 FY2027 from $457M, due to higher working capital and inventory.
  • Cash used in financing was $1.3B in Q1 FY2027, driven by $936M in treasury stock repurchases vs $150M a year ago.

• Unregistered Sales and Repurchases (Item 2)

  Large buyback pace and new $450M ASR agreement; material capital allocation detail.
  Notable

  • Since 2014 program approval, 15.7M shares repurchased for $2.4B through Sep 30, 2026.
  • New $450M ASR agreement entered Aug 31, 2026; initial 1.6M shares delivered, final by Dec 29.

What changed: Sep 2026 vs. Mar 2026

About 20% of RMD's Sep 2026 10-Q is new information. 52 paragraphs were added, 120 changed, and 72 removed. Below are the most important lines SECSift identified.

• Item 2 66
• Item 1 63
• Item 3 7
• Item 6 2
• Item 5 2
• Item 4 1
• Item 1A 1